METTL3 Promotes the Resistance of Glioma to Temozolomide via Increasing MGMT and ANPG in a m(6)A Dependent Manner

Acquired chemoresistance is a major limiting factor in the clinical treatment of glioblastoma (GBM). However, the mechanism by which GBM acquires therapeutic resistance remains unclear. Here, we aimed to investigate whether METTL3-mediated N6-methyladenosine (m(6)A) modification contributes to the t...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Jia, Chen, Gang, Dong, Xuchen, Li, Haoran, Li, Suwen, Cheng, Shan, Li, Yongdong, Wang, Liping, Yuan, Jiaqi, Qian, Zhiyuan, Dong, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8320395/
https://www.ncbi.nlm.nih.gov/pubmed/34336690
http://dx.doi.org/10.3389/fonc.2021.702983

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8320395/
https://www.ncbi.nlm.nih.gov/pubmed/34336690
http://dx.doi.org/10.3389/fonc.2021.702983

Ejemplares similares